Zhao J, Zhi Z, Wang C, Xing H, Song G, Yu X, et al
Ethical approval This study was approved by the Experimental Animals Local Ethics Committee of Atatrk University (Date:27.04.2018/Number:100)
Data on the cardio-renal and metabolic outcomes, the long-term efficacy and safety as well as the cost-effectiveness for each of the novel pharmacotherapies will allow clinicians to offer better individualized care for people with T2D and will also provide a better understanding of their potential position at the T2D treatment guidelines
Ready to Explore Peptide Therapy
CJC-1295 is a GHRH analog that promotes sustained, physiologic growth hormone pulses from the pituitary
For many patients, one IV session per month provides more measurable benefit than daily oral supplements that cost the same annually